WHO Condemns Unethical Hepatitis B Birth Dose Vaccine Trial

The World Health Organization (WHO) has expressed serious ethical and scientific concerns regarding a proposed randomized controlled trial (RCT) in Guinea-Bissau examining the timing of the hepatitis B birth dose vaccine. The trial, funded by the U.S. Centers for Disease Control and Prevention (CDC), would withhold the vaccine from some newborns, a practice the WHO deems unethical given the vaccine’s proven efficacy and safety record. This development comes amid broader scrutiny of vaccine policies under the current U.S. Administration.

Hepatitis B is a significant global health threat, with an estimated 254 million people living with chronic infection in 2022, according to the WHO. The virus attacks the liver and can lead to cirrhosis and liver cancer, resulting in approximately 1.1 million deaths annually. Preventing transmission at birth through vaccination is a cornerstone of global elimination efforts, and the birth dose is currently included in national immunization schedules in over 115 countries.

The core of the WHO’s objection lies in the study’s design, which proposes to randomize newborns to receive the hepatitis B vaccine either at birth or at six weeks of age. The WHO argues that withholding a proven, life-saving intervention from a control group is ethically unacceptable. “A study which provides the hepatitis B birth dose vaccine, a proven lifesaving intervention, but withholds it from some study participants exposes newborns to serious and potentially irreversible harm,” the WHO stated. This harm includes the risk of chronic infection, cirrhosis, and liver cancer.

Why Withholding the Vaccine is Considered Unethical

The WHO’s concerns extend beyond the immediate risk to newborns. The organization emphasizes that placebo-controlled vaccine trials are only justifiable when no effective intervention exists or when the study design is essential to answer a critical question of efficacy or safety. Neither of these conditions appears to be met in the proposed Guinea-Bissau trial. Publicly available information suggests the study doesn’t challenge the vaccine’s effectiveness but instead explores hypothetical safety outcomes without sufficient evidence of a safety signal warranting the risk to participants. The WHO also points to a biased study design – a single-blind, no-treatment-controlled approach – which could limit the interpretability of the results.

the WHO asserts that exploiting resource constraints to justify withholding proven care is unethical. The organization stresses that ethical obligations require minimizing risk and ensuring a prospect of benefit for all participants. The proposed protocol, as described, does not appear to guarantee even a basic level of harm reduction, such as screening pregnant women for hepatitis B and providing prophylaxis to exposed newborns.

Guinea-Bissau Suspends Trial, WHO Offers Support

The WHO has confirmed that Guinea-Bissau has suspended the study pending further technical reviews. The organization has pledged to support Guinea-Bissau in accelerating the introduction of the birth dose vaccine and strengthening its implementation through strategies like timely delivery within 24 hours of birth, antenatal screening for hepatitis B surface antigen (HBsAg), and robust cold-chain logistics. The WHO also highlighted the importance of monitoring vaccine coverage and pharmacovigilance to ensure continuous improvement.

The situation in Guinea-Bissau is particularly concerning given the country’s high prevalence of chronic hepatitis B. According to the WHO, over 12% of adults in Guinea-Bissau are estimated to be living with chronic hepatitis B (as of 2022), and the infection rate in children under five – around 2% in 2020 – is significantly above the global target of ≤0.1%. Notably, Guinea-Bissau formally decided in 2024 to add the hepatitis B birth dose to its national immunization schedule, with full implementation planned by 2028, a decision that underscores the vaccine’s recognized value.

The WHO remains committed to working with national authorities, researchers, and partners to ensure all newborns worldwide receive timely, evidence-based protection against hepatitis B. The organization emphasizes the importance of conducting research in this area to the highest ethical and scientific standards.

Disclaimer: This article provides informational content about public health and is not intended to be a substitute for professional medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment of any medical condition.

The ongoing situation highlights the critical importance of adhering to rigorous ethical guidelines in medical research and prioritizing the health and well-being of vulnerable populations. The next steps will be closely watched as Guinea-Bissau evaluates the trial and determines its path forward in combating hepatitis B.

What are your thoughts on the ethical considerations of vaccine trials? Share your perspective in the comments below.